Top

Published in:

01-08-2016 | Health Economics and Quality of Life (M Harrison, Section Editor)

Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences

Authors: Axel Finckh, Monica Escher, Matthew H. Liang, Nick Bansback

Published in: Current Rheumatology Reports | Issue 8/2016

Abstract

The detection of biomarkers in the preclinical phase of rheumatoid arthritis (RA) and recent therapeutic advances suggest that it may be possible to identify and treat persons at high risk and to prevent the development of RA. Several trials are ongoing to test the efficacy of a therapeutic intervention in primary prevention. This paper reviews potential populations that might be considered for preventative medication. Further, we review the medications that are being explored to treat individuals considered at high risk of developing RA. Finally, in a group of asymptomatic individuals at high risk of developing RA, we assessed which factors mattered most when considering a preventive therapeutic intervention and what type of preventive treatment would be most acceptable to them. Understanding subjects’ perceptions of risks and benefits and willingness to undergo preventive therapy will be important in designing and implementing screening and preventive strategies.

Available only for authorised users

Majka DS, Holers VM. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? Arthritis Rheum. 2003;48(10):2701–5.CrossRefPubMed

Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today. 1994;15(3):115–20.CrossRefPubMed

Van Dongen H, Van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56(5):1424–32.CrossRefPubMed

Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–6.CrossRefPubMed

Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–9.CrossRefPubMed

McClure A, Lunt M, Eyre S, Ke X, Thomson W, Hinks A, et al. Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. Rheumatology (Oxford). 2009;48(11):1369–74.CrossRef

Organisation WH, editor. Preventing chronic disease: a vital investment. WHO Press; 2005.

Neuner JM, Schapira MM. Patient perceptions of osteoporosis treatment thresholds. J Rheumatol. 2014;41(3):516–22. doi:10.3899/jrheum.130548.CrossRefPubMedPubMedCentral

Harmsen CG, Stovring H, Jarbol DE, Nexoe J, Gyrd-Hansen D, Nielsen JB, et al. Medication effectiveness may not be the major reason for accepting cardiovascular preventive medication: a population-based survey. BMC Med Inform Decis Mak. 2012;12:89. doi:10.1186/1472-6947-12-89.CrossRefPubMedPubMedCentral

10.•

Novotny F, Haeny S, Hudelson P, Escher M, Finckh A. Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk population. Joint Bone Spine. 2013;80(6):673–4. doi:10.1016/j.jbspin.2013.05.005. A qualitative study exploring expectations and level of interest of high-risk individuals for RA regarding preventive interventions. Identified a minimum level of risk for developing RA above which participants are considering taking prophylactic treatment.CrossRefPubMed

11.

Laba TL, Brien JA, Fransen M, Jan S. Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskelet Disord. 2013;14:160. doi:10.1186/1471-2474-14-160.CrossRefPubMedPubMedCentral

12.

Fraenkel L, Bogardus Jr ST, Concato J, Wittink DR. Treatment options in knee osteoarthritis: the patient’s perspective. Arch Intern Med. 2004;164(12):1299–304. doi:10.1001/archinte.164.12.1299.CrossRefPubMed

13.

Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012;7(1):e28238. doi:10.1371/journal.pone.0028238.CrossRefPubMedPubMedCentral

14.

Maisonneuve AS, Huiart L, Rabayrol L, Horsman D, Didelot R, Sobol H, et al. Acceptability of cancer chemoprevention trials: impact of the design. Int J Med Sci. 2008;5(5):244–7.CrossRefPubMedPubMedCentral

15.

Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One. 2008;3(5):e2267. doi:10.1371/journal.pone.0002267.CrossRefPubMedPubMedCentral

16.

Silman AJ, Hennessy E, Ollier B. Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol. 1992;31(6):365–8.CrossRefPubMed

17.•

Chibnik LB, Keenan BT, Cui J, Liao KP, Costenbader KH, Plenge RM, et al. Genetic risk score predicting risk of rheumatoid arthritis phenotypes and age of symptom onset. PLoS One. 2011;6(9):e24380. The study proposes a combination of various genetic risk factors combined into a single measure of genetic risk (genetic risk score).CrossRefPubMedPubMedCentral

18.

Costenbader KH, Karlson EW. Epstein-Barr virus and rheumatoid arthritis: is there a link? Arthritis Res Ther. 2006;8(1):204.CrossRefPubMedPubMedCentral

19.

Hart JE, Laden F, Puett RC, Costenbader KH, Karlson EW. Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environ Health Perspect. 2009;117(7):1065–9.CrossRefPubMedPubMedCentral

20.

Lu B, Solomon DH, Costenbader KH, Keenan BT, Chibnik LB, Karlson EW. Alcohol consumption and markers of inflammation in women with preclinical rheumatoid arthritis. Arthritis Rheum. 2010;62(12):3554–9.CrossRefPubMedPubMedCentral

21.

Kallberg H, Jacobsen S, Bengtsson C, Pedersen M, Padyukov L, Garred P, et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis. 2009;68(2):222–7.CrossRefPubMed

22.

Karlson EW, Mandl LA, Hankinson SE, Grodstein F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses’ Health Study. Arthritis Rheum. 2004;50(11):3458–67.CrossRefPubMed

23.

Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46.CrossRefPubMed

24.

Criswell LA, Saag KG, Mikuls TR, Cerhan JR, Merlino LA, Lum RF, et al. Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women. Ann Rheum Dis. 2006;65(9):1163–7.CrossRefPubMedPubMedCentral

25.

Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004.

26.

Keenan BT, Chibnik LB, Cui J, Ding B, Padyukov L, Kallberg H, et al. Effect of interactions of glutathione S-transferase T1, M1, and P1 and HMOX1 gene promoter polymorphisms with heavy smoking on the risk of rheumatoid arthritis. Arthritis Rheum. 2010;62(11):3196–210.CrossRefPubMedPubMedCentral

27.

Jorgensen KT, Wiik A, Pedersen M, Hedegaard CJ, Vestergaard BF, Gislefoss RE, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis. 2008;67(6):860–6. doi:10.1136/ard.2007.073825.CrossRefPubMed

28.

Karlson EW, Chibnik LB, Tworoger SS, Lee IM, Buring JE, Shadick NA, et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum. 2009;60(3):641–52. doi:10.1002/art.24350.CrossRefPubMedPubMedCentral

29.

Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797–808.CrossRefPubMed

30.

Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65(7):845–51.CrossRefPubMedPubMedCentral

31.••

Karlson EW, Ding B, Keenan BT, Liao K, Costenbader KH, Klareskog L, et al. Association of environmental and genetic factors and gene-environment interactions with risk of developing rheumatoid arthritis. Arthritis Care Res. 2013;65(7):1147–56. doi:10.1002/acr.22005. Illustrates how both genetic tests and epidemiologic risk factors can be combined to identify individuals at high risk of developing RA.CrossRef

32.

Sparks JA, Chen CY, Jiang X, Askling J, Hiraki LT, Malspeis S, et al. Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-205009.PubMedCentral

33.

Scott IC, Seegobin SD, Steer S, Tan R, Forabosco P, Hinks A, et al. Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PLoS Genet. 2013;9(9):e1003808. doi:10.1371/journal.pgen.1003808.CrossRefPubMedPubMedCentral

34.

Turk SA, van Beers-Tas MH, van Schaardenburg D. Prediction of future rheumatoid arthritis. Rheum Dis Clin N Am. 2014;40(4):753–70. doi:10.1016/j.rdc.2014.07.007.CrossRef

35.••

van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis. 2013;72(12):1920–6. doi:10.1136/annrheumdis-2012-202127. Proposes a functional prediction rule to identify individuals at high risk of developing RA.CrossRefPubMed

36.

Karlson EW, van Schaardenburg D, van der Helm-van Mil AH. Strategies to predict rheumatoid arthritis development in at-risk populations. Rheumatology (Oxford). 2016;55(1):6–15. doi:10.1093/rheumatology/keu287.CrossRef

37.

Klareskog L, Gregersen PK, Huizinga TW. Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis. 2010;69(12):2062–6. doi:10.1136/ard.2010.142109.CrossRefPubMed

38.

Bykerk VP, Hazes JM. When does rheumatoid arthritis start and can it be stopped before it does? Ann Rheum Dis. 2010;69(3):473–5. doi:10.1136/ard.2009.116020.CrossRefPubMed

39.

Deane KD. Can rheumatoid arthritis be prevented? Best Pract Res Clin Rheumatol. 2013;27(4):467–85. doi:10.1016/j.berh.2013.09.002.CrossRefPubMedPubMedCentral

40.

Finckh A, Deane KD. Prevention of rheumatic diseases: strategies, caveats, and future directions. Rheum Dis Clin N Am. 2014;40(4):771–85. doi:10.1016/j.rdc.2014.07.010.CrossRef

41.

de Jong HJ, Klungel OH, van Dijk L, Vandebriel RJ, Leufkens HG, van der Laan J, et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis. 2012;71:648–54.CrossRefPubMed

42.

Tascilar K, Dell’Aniello S, Hudson M, Suissa S. Statins and the risk of rheumatoid arthritis—a population based study from the General Practice Research Database. Quebec City: Canadian Rheumatology Association Annual Meeting; 2015.

43.

Gan RW, Young KA, Zerbe GO, Demoruelle MK, Weisman MH, Buckner JH, et al. Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. Rheumatology (Oxford). 2016;55(2):367–76. doi:10.1093/rheumatology/kev266.CrossRef

44.

Bos WH, Dijkmans BA, Boers M, van de Stadt RJ, van Schaardenburg D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2010;69(3):571–4. doi:10.1136/ard.2008.105767.CrossRefPubMed

45.

Tak P. Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease. In: Nederland Trial Register. Dutch Cochrane Centre, Academisch Medisch Centrum, Amsterdam. 2012. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2442. Accessed 18 July 2012.

46.

Tak PP. Towards prevention of RA by B cell directed therapy: the PRAIRI study. 36th Eueopean Workshop for Rheumatology Research; 2016 27 Feb 2016; York.

47.

Neff T. Rheumatoid arthritis prevention study getting ready to roll. UCHealth Insider 2015.

48.

Al-Laith M, Cope AP. Arthritis prevention in the pre-clinical phase of rheumatoid arthritis with abatacept (APIPPRA). ISRCTN registry 2014.

49.

van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337–51. doi:10.1586/eci.12.23.CrossRefPubMed

50.

Finckh A, Müller R, Möller B, Dudler J, Kyburz D, Walker U et al. A novel screening strategy for preclinical rheumatoid arthritis (RA) in first degree relatives of patients with RA. Annual European Congress of Rheumatology EULAR; 2011; London: Ann Rheum Dis.

51.

Aslibekyan S, Sha J, Redden DT, Moreland LW, O’Dell JR, Curtis JR, et al. Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis. Ann Rheum Dis. 2014;73(4):785–6. doi:10.1136/annrheumdis-2013-204263.CrossRefPubMed

52.

Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol. 2003;30(11):2350–5.PubMed

53.

Kanninen BJ. Optimal design for multinomial choice experiments. J Mark Res. 2002;39(2):214–27.CrossRef

54.

Nichols, Austin, Schaffer M. Clustered errors in Stata. ited Kingdom Stata Users’ Group Meeting; 2007.

55.

Tak P. Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease. PRAIRI. In: International Clinical Trials Platform. WHO, Geneva. 2010. Accessed 13 March 2012.

56.

Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, et al. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective. J Rheumatol. 2005;32(3):443–53.PubMed

57.

Taylor HA, Sugarman J, Pisetsky DS, Bathon J. Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials. Ann Rheum Dis. 2007;66(4):542–4.CrossRefPubMedPubMedCentral

58.

Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28(18):3090–5. doi:10.1200/JCO.2009.27.8077.CrossRefPubMedPubMedCentral

59.

Waters EA, Weinstein ND, Colditz GA, Emmons K. Explanations for side effect aversion in preventive medical treatment decisions. Health Psychol. 2009;28(2):201–9. doi:10.1037/a0013608.CrossRefPubMedPubMedCentral

60.

Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. BMJ. 2012;345:e3953. doi:10.1136/bmj.e3953.CrossRefPubMedPubMedCentral

61.

Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM. Why do women reject bisphosphonates for osteoporosis? A videographic study. PLoS One. 2011;6(4):e18468. doi:10.1371/journal.pone.0018468.CrossRefPubMedPubMedCentral

62.

Fried TR, Tinetti ME, Towle V, O’Leary JR, Iannone L. Effects of benefits and harms on older persons’ willingness to take medication for primary cardiovascular prevention. Arch Intern Med. 2011;171(10):923–8. doi:10.1001/archinternmed.2011.32.CrossRefPubMedPubMedCentral

63.

Llewellyn-Thomas HA, Paterson JM, Carter JA, Basinsk A, Myers MG, Hardacre GD, et al. Primary prevention drug therapy: can it meet patients’ requirements for reduced risk? Med Decis Mak. 2002;22(4):326–39.CrossRef

64.

Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. Patient Educ Couns. 2007;65(2):237–44. doi:10.1016/j.pec.2006.08.004.CrossRefPubMed

65.

Smerecnik CM, Mesters I, Verweij E, de Vries NK, de Vries H. A systematic review of the impact of genetic counseling on risk perception accuracy. J Genet Couns. 2009;18(3):217–28. doi:10.1007/s10897-008-9210-z.CrossRefPubMed

66.

Carling CL, Kristoffersen DT, Montori VM, Herrin J, Schunemann HJ, Treweek S, et al. The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial. PLoS Med. 2009;6(8):e1000134. doi:10.1371/journal.pmed.1000134.CrossRefPubMedPubMedCentral

67.

Peters E, Hart PS, Fraenkel L. Informing patients: the influence of numeracy, framing, and format of side effect information on risk perceptions. Med Decis Mak. 2011;31(3):432–6. doi:10.1177/0272989X10391672.CrossRef

68.

Elwyn G, O’Connor A, Bennett C, Newcombe R, Politi M, Durand M, et al. Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi). PLoS One. 2010;4(3):e4705.CrossRef

Title: Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences
Authors: Axel Finckh
Monica Escher
Matthew H. Liang
Nick Bansback
Publication date: 01-08-2016
Publisher: Springer US
Published in: Current Rheumatology Reports / Issue 8/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-016-0598-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

Juvenile Spondyloarthropathies

Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?

Neuromyelitis Optica (Devic’s Syndrome): an Appraisal

Histone Deacetylases in Cartilage Homeostasis and Osteoarthritis

Erectile Dysfunction in Systemic Sclerosis

The Role of MicroRNAs and Their Targets in Osteoarthritis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage